1. Scrip
  2. >>Drug Pricing

ICER Says Amgen/Novartis Migraine Drug Aimovig Is Cost Effective At $5,000 Net Price

 
• By Mandy Jackson

Amgen said when Aimovig was approved that its $6,900 list price was designed to make sure a lot of patients could access the migraine prophylaxis. ICER now says that's a reasonable price, assuming a $5,000 net cost for the CGRP inhibitor, but only for patients who have failed on other treatments.

Profile of a human head with a colorful symbol of neurons in the brain

The price for Amgen Inc.'s and Novartis AG's first-in-class calcitonin gene-related peptide (CGRP) inhibitor Aimovig (erenumab-aooe), approved recently in the US for migraine headaches, won an endorsement from the Institute for Clinical and Economic Review (ICER) – at least in patients with chronic migraines who haven't been helped by older preventative therapies.

ICER released a revised assessment of CGRP inhibitor costs on May 31 based on Aimovig's list price of $575 per month, or $6,900 annually

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.